^
    Apply
    Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer (KontRASt-02) (NCT05132075)
    Phase 3
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    06/23/2022
    Primary completion :
    10/01/2025
    Completion :
    10/31/2025
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    docetaxel • opnurasib (JDQ443)
    Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation. (NCT05445843)
    Phase 2
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    06/11/2024
    Initiation :
    12/06/2022
    Primary completion :
    11/02/2026
    Completion :
    11/30/2027
    PD-L1 • KRAS • STK11
    |
    PD-L1 expression • KRAS mutation • KRAS G12C • STK11 mutation • KRAS G12 • KRAS G12C + PD-L1 expression
    |
    opnurasib (JDQ443)
    Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (KontRASt-01) (NCT04699188)
    Phase 1/2
    Novartis Pharmaceuticals
    Recruiting
    Last update posted :
    06/04/2024
    Initiation :
    02/24/2021
    Primary completion :
    01/08/2027
    Completion :
    01/08/2027
    KRAS
    |
    KRAS mutation
    |
    Tevimbra (tislelizumab-jsgr) • spartalizumab (PDR001) • batoprotafib (TNO155) • opnurasib (JDQ443)
    JDQ443 for KRAS G12C NSCLC Brain Metastases (STRIDER) (NCT05999357)
    Phase 2
    Maastricht University Medical Center
    Withdrawn
    Last update posted :
    05/29/2024
    Initiation :
    04/15/2024
    Primary completion :
    08/01/2027
    Completion :
    08/01/2028
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    opnurasib (JDQ443)
    Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (KontRASt-03) (NCT05358249)
    Phase 1/2
    Novartis Pharmaceuticals
    Recruiting
    Last update posted :
    02/09/2024
    Initiation :
    10/24/2022
    Primary completion :
    05/05/2027
    Completion :
    06/16/2027
    KRAS
    |
    Erbitux (cetuximab) • Mekinist (trametinib) • Kisqali (ribociclib) • opnurasib (JDQ443)